A Multiple-Centered, Prospective Cohort Study: the Second Prevention Trial for Ischemic Stroke With Deng Zhan Sheng Mai Capsule（SPIRIT-DZSM-2）
NCT ID: NCT00547950
Last Updated: 2007-10-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
12000 participants
INTERVENTIONAL
2007-11-30
2009-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
drug
:Deng Zhan Sheng Mai Capsule
capsule，0.18g，2＃，po，Bid\*1year.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
:Deng Zhan Sheng Mai Capsule
capsule，0.18g，2＃，po，Bid\*1year.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ischemic stroke diagnosed by CT/MRI scan
* Patient presenting from 14 days to 6 months of first onset of Ischemic stroke.
* Presence of at least one risk factor of stroke (such as hypertension, Diabetes mellitus, coronary heart disease, hyperlipidemia, and smoking, etc.)that can be interfered in.
* Informed consent.
Exclusion Criteria
* Patients after vasculoplasty with Intracranial Artery Stenosis.
* Watian drinking test≥grade 4.
* MRS=grade 5.
* Cerebral infarction due to other causes except arterial Sclerosis(i.e. cardiogenic embolism, arteritis, polycythemia vera, primary thrombocythemia, sickle-cell anemia,, thrombotic thrombocytopenia purpura, DIC, cerebral amyloid angiopathy, Moyamoya disease, intracranial vascular malformations etc);
* Presence of serious heart disease, heart, liver, lung, and kidney functional failure; malignancy; alimentary tract hemorrhage;
* Patients with mental disorder.
* Patients that cannot take medicine due to other causes
* Females during pregnancy or lactation.
* Already attend other clinical trial.
* That unsuitable for clinical trial.
40 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guangzhou University of Traditional Chinese Medicine
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yan Huang, Bachelor
Role: PRINCIPAL_INVESTIGATOR
Guangdong Province Hospital of Tradtional Chinese Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guangdong Province Hospital of Tradtional Chinese Medicine
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Lixin Wang, Doctor
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2006BAI04A02-2
Identifier Type: -
Identifier Source: org_study_id